Founders & Management
Samedy Ouk - President and CEO
Dr. Ouk is a co-founder of ImmuneTarget and has served as its CEO and President since 2015. Dr. Ouk earned his Ph.D. in Chemistry in 2002 from ENSIACET/INP-Toulouse (France), where he developed novel processes of methylation phenols and NH-containing heterocyclic molecules with environmentally friendly reagents, dimethyl carbonate.
From 2003 to 2005, he worked as a postdoctural fellow with Dr. Charles Sawyers and Dr. Michael Jung at UCLA, where he invented two prostate cancer drugs, Xtandi® (enzulatamide) and Erleada® (apalutamide).
Since 2005, Dr. Ouk has worked in the biotech and pharmaceutical industry. He worked at Valeant Pharmaceuticals, and Ardea Biosciences as a principal chemist in the areas of CNS, antivirals, and inflammation. At Ardea, his main task was to provide chemistry support for clinical development of a gout drug, Vesinurad. In addition to the main assignment, he invented two series of molecules, one of which became the follow-up clinical development drug candidate, RDEA3170 (Verinurad).
Dr. Ouk earned an MBA from the UCLA Anderson School of Management. He hsa been a recipient of AUPELF-UREF fellowship, French government scholarships, and the NIH-SPORE grant.
Hsiou-Chi Liou - Co-founder and Chairperson
Dr. Liou is a co-founder of ImmuneTarget, and previously served as ImmuneTarget CEO from its inception until 2015.
She received a Ph.D. from Harvard University in 1989 under the supervision of Dr. Laurie H. Glimcher, and completed a post-doctural fellowship at MIT and Rockefeller University under the direction of Dr. David Baltimore. She subsequently held a faculty position from 1994 to 2011 at the Weill Medical College of Cornell University, where she received over $6 million in federal and private funding to pioneer research in molecular biology, cell biology, and immunology. Her team generated one of the c-Rel knockout mouse models and discovered the NF-kB/Rel inhibitors.
Dr. Liou's experience also extends to finance and investments. She is a CFA charterholder and served as an equity analyst at Biovantage Investments from 2012 to 2014. As a portfolio advisor at Bank of America Merrill Lynch, she manages investment portfolios for executives of biotech companies and professionals in the healthcare industry.
Dr. Liou has been the recipient of many prestigious awards, including the Scholar Award by the Leukemia and Lymphoma Society, the Junior Faculty Research Award by the American Cancer Society, the Basil O'Connor Scholar award by the March of Dimes Foundation, the First Prize winner for the Medicine Investigator Award sponsored by the Michael Wolk Heart Foundation, and the Government Scholarship Award of Biotechnology for Overseas Study (Taiwan).